SummaryRMgm-5032
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 34119684 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Yuda M, Nishi T |
Name Group/Department | Department of Medical Zoology |
Name Institute | Mie University School of Medicine |
City | Mie, Tsu |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5032 |
Principal name | AP2R-1(-) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | two independent disruptants were obtained. Mature-appearing female and male gametocytes were observed in Giemsa-stained blood smears. However, in ookinete culture, they failed to develop into mature ookinetes. In mosquito transmission experiments, no oocysts were found in the midgut 14 days after mosquito blood-feeding. |
Fertilization and ookinete | two independent disruptants were obtained. Mature-appearing female and male gametocytes were observed in Giemsa-stained blood smears. However, in ookinete culture, they failed to develop into mature ookinetes. In mosquito transmission experiments, no oocysts were found in the midgut 14 days after mosquito blood-feeding. |
Oocyst | Two independent disruptants were obtained. Mature-appearing female and male gametocytes were observed in Giemsa-stained blood smears. However, in ookinete culture, they failed to develop into mature ookinetes. In mosquito transmission experiments, no oocysts were found in the midgut 14 days after mosquito blood-feeding. |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation See also mutants RMgm-5199 and RMgm-5200 targeting this gene by the same group with a different expression pattern when the gene was tagged with GFP (as a result of translational repression in female gametocytes). Additional information Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0612400 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0411000 | ||||||||||||||||||||||||
Gene product | conserved Plasmodium protein, unknown function | ||||||||||||||||||||||||
Gene product: Alternative name | AP2R-1, AP2-R1 (AP2 Transcription Factor-related gene 1), AP2-Z (AP2-zygote) | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |